CHEMBIO DIAGNOSTIC SYSTEMS AWARDED $5.7 MILLION TO ADVANCE DPP® BIOTHREAT PANEL Medford, N.Y., USA / Strasbourg, France – September 23, 2026– Chembio Diagnostic Systems, Inc. (Chembio), a wholly owned subsidiary…
QUALIGEN DIAGNOSTICS ANNOUNCE AGREEMENT WITH AFAXYS GPO TO EXPAND ACCESS TO FASTPACK® IP QUANTITATIVE hCG TESTING IN WOMEN'S HEALTH Carlsbad, C.A., USA / Strasbourg, France – March 20, 2026 –…
CHEMBIO DIAGNOSTIC SYSTEMS, INC., A BIOSYNEX SUBSIDIARY, RECEIVES $1.8 MILLION CARB-X GRANT TO DEVELOP A RAPID DIAGNOSTIC TEST FOR TYPHOID FEVER Medford, N.Y., USA / Strasbourg, France – February 6,…
CHEMBIO DIAGNOSTIC SYSTESMS INC., A SUBSIDIARY OF BIOSYNEX, ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS TnT ASSAY FOLLOWING BREAKTHROUGH DEVICE DESIGNATION Medford, N.Y., USA / Strasbourg, France – January 22,…
